Diagnosis: Major Depression
- Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating Major Depression Disorder in children and adolescents.
- Explain the risk assessment you would use to inform your treatment decision making.
- What are the risks and benefits of the FDA-approved medicine?
- What are the risks and benefits of the off-label drug?
- Explain whether clinical practice guidelines exist for Major Depression Disorder and, if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration.
- Support your reasoning with at least three scholarly resources, one each on the FDA-approved drug, the off-label, and a non-medication intervention for the disorder. Attach the PDFs of your sources.
2 Pages,
References x 3
- Hilt, R. J., & Nussbaum, A. M. (2016). DSM-5 pocket guide for child and adolescent mental healthLinks to an external site.. American Psychiatric Association Publishing.
- Chapter 14, “Psychosocial Interventions”
- Chapter 15, “Psychotherapeutic Interventions”
- Chapter 16, “Psychopharmacological Interventions”Links to an external site.
- Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and adolescent psychiatry (6th ed.). Wiley Blackwell.
- Chapter 43, “Pharmacological, Medically-Led and Related Treatments”
CriticalThinkRx. (2019, June 9). Module 5: Links to an external site.Specific drug classes: Focus on adverse effectsLinks to an external site. [Video]. YouTube. https://youtu.be/Gbq6RnOsGKQ
